GHRP-2 Dosage Chart: 100-300mcg Community Protocol

GHRP-2 (pralmorelin, KP-102) is one of the most clinically studied growth hormone releasing peptides. Originally developed as a diagnostic tool for GH deficiency, it has become a reference compound for understanding how synthetic ghrelin mimetics drive pulsatile GH release. GHRP-2 is not FDA-approved for therapeutic use. This is not medical advice.

Research-context information only. GHRP-2 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Note: GHRP-2 has no standardized clinical dosing protocol for this use. The protocol below is a Community Protocol based on clinical research data and community experience.

Quick Reference: Community Protocol

Most common approach: 100-200 mcg per injection (the clinical research range), 2-3 times daily on empty stomach. Common timing: morning fasted, pre-workout, and before bed.

Cycling Details

GHRP-2 doesn't use loading phases. Documented community protocols describe consistent 100-300 mcg doses, 2-3 times daily, 5 days on / 2 days off. A five-day treatment study showed response attenuation with consecutive daily use (Raun et al., 1998), making the 5-on/2-off pattern important.

8 weeks on, 8 weeks off is the common community pattern for long-term cycling, generally for cost and to let IGF-1 and the HPA axis normalize. The short half-life (~15-30 minutes) means each injection provides an acute GH pulse rather than sustained elevation. For how the ghrelin and GHRH peptide families differ on desensitization, see Do GH Peptides Desensitize the Pituitary?.

Empty stomach timing: Documented protocols describe injecting 30-60 minutes before eating or 2+ hours after meals. Elevated blood glucose and free fatty acids significantly blunt the GH response.

Community-reported timing clusters around morning fasted + before bed (2x/day), or morning fasted + pre-workout + before bed (3x/day).

Routes of Administration

Subcutaneous injection (standard): Belly fat, thigh, or anywhere with SC tissue. Volume: 0.1-0.2 mL with insulin syringe (29-31 gauge). Trial protocols describe rotating injection sites.

Reconstitution Quick Reference

Math: 10,000 mcg / 5 mL = 2,000 mcg/mL. For 200 mcg: 200 / 2,000 = 0.1 mL = 10 units. One vial lasts 50 doses at 200 mcg.

Community reconstitution protocols describe gentle swirling, not shaking, then refrigeration at 2-8°C and use within 28 days. For step-by-step instructions, see the Reconstitution Calculator.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

Unlike many research peptides, GHRP-2 community doses closely align with published clinical research.

Diagnostic testing: 100 mcg (1 mcg/kg) is the standard dose for GH deficiency diagnosis, producing robust GH pulses in healthy individuals (PMID: 17609397).

Research studies: 200 mcg (2-3 mcg/kg) used in studies examining GH secretory dynamics (PMID: 18703567).

Plateau effect: Higher doses (300+ mcg) don't increase GH proportionally but do increase cortisol and prolactin side effects.

GH response data (trial-reported): Published studies report peak GH levels of 30-80 ng/mL at 100-200 mcg doses. Time to peak: 30-60 minutes, duration approximately 2-3 hours elevated (PMID 17609397; PMID 18703567). GHRH co-administration produces 3-10x greater response than either alone (Veldhuis et al., 2009).

Why doses align with research: GHRP-2 is approved in Japan as pralmorelin for GH testing. This established effective dose ranges directly, unlike most peptides that require extrapolation from animal studies.

Stacking Protocols

GHRP-2 + GHRH synergy leverages two different receptor pathways: GHRP-2 via GHSR-1a (calcium/PKC) and CJC-1295 via GHRHR (cAMP/PKA) (Veldhuis et al., 2009).

For comprehensive stacking strategies, see our Peptide Stacking Guide.

Side Effects & Safety

• Cortisol elevation -- transient ACTH/cortisol increase via HPA axis; dose-dependent, mild at 100-200 mcg
• Prolactin elevation -- less than hexarelin, more than ipamorelin; returns to baseline within 2-3 hours
• Appetite stimulation -- ghrelin mimetic effect, peaks 20-30 min post-injection; milder than GHRP-6
• Water retention -- mild, GH-mediated sodium retention
• Response attenuation -- a five-day study reported declining GH response with consecutive daily use (Raun et al., 1998); community sources use 5-on/2-off to manage this
• Injection site reactions -- standard for SC peptides

GHRP family comparison:

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once GHRP-2 is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 10 mg vial + 5 mL BAC water (2 mg/mL) — the standard dilution from the Quick Reference above.

Reconstitution B: 10 mg vial + 10 mL BAC water (1 mg/mL) — more BAC water for larger, easier-to-measure draws.

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.